Walgreens Boots Alliance, Inc. - Common Stock (WBA)
10.06
-1.40 (-12.22%)
Walgreens Boots Alliance is a global healthcare leader that operates a chain of pharmacies, drugstores, and health and wellness retail outlets
The company is known for providing accessible pharmaceutical services and a wide range of health and beauty products. With a commitment to enhancing the health and well-being of its customers, Walgreens Boots Alliance focuses on delivering innovative healthcare solutions, including pharmacy services, immunizations, and health consultations. Additionally, the company engages in retail pharmacy and wholesale distribution, partnering with various healthcare providers to improve patient outcomes and ensure the availability of essential medications and healthcare products.
Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced that its board of directors is suspending the company’s cash dividend historically paid to stockholders on a quarterly basis, as management continues to evaluate and refine its capital allocation policy consistent with the company’s broader long-term turnaround efforts.
Curious about the top performers within the S&P500 index in the middle of the day on Tuesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
RANCHO CORDOVA, Calif. - Hanley Investment Group Real Estate Advisors, a nationally recognized real estate brokerage and advisory firm specializing in retail property sales, announced today that the firm arranged the sale of a new construction, 9,000-square-foot multi-tenant retail pad, Shops II, at the new Anatolia Marketplace shopping center in Rancho Cordova, California, an affluent suburb in the Sacramento metro area. The sale price was $6.08 million.
The S&P 500 index has done well over the years. Companies like Walgreens, Pfizer, and Ford are high-yielding. Other high-yielding S&P 500 index stocks are Altria and Franklin Resources.
Shares of pharmacy chain Walgreens Boots Alliance (NASDAQWBA) fell 12.3% in the morning session after the US Department of Justice accused the company (Walgreens) of filling millions of unlawful opioid prescriptions. According to the complaint, Walgreens overlooked major red flags and pressured pharmacists to dispense these medications, then sought reimbursement from federal programs in violation of the False Claims Act. Although Walgreens denies any wrongdoing, the stock's reaction suggests investors are wary of the uncertainty this legal battle may create.
